In the case of T2DM caused by β‐cell dysfunction or insulin resistance, synthetic agonist (glucagon‐like peptide GLP) targeting glucagon‐like peptide 1 receptor (GLP1R) showed promising therapeutic effects.30 Here, GLP1R is linked to type 2 diabetes mellitus.